iSERA Lifesciences Ltd
- Market Cap ₹ 121 Cr.
- Current Price ₹ 144
- High / Low ₹ 144 / 5.21
- Stock P/E
- Book Value ₹ 9.81
- Dividend Yield 0.00 %
- ROCE 5.95 %
- ROE 6.38 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 14.7 times its book value
- Company has high debtors of 322 days.
- Promoter holding has decreased over last 3 years: -41.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.90 | 25.50 | 21.36 | 28.92 | 12.30 | 2.13 | 2.13 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36 | 1.35 | |
| 10.28 | 25.14 | 20.92 | 28.46 | 11.98 | 2.19 | 0.19 | 0.11 | 0.11 | 0.09 | 0.13 | 1.09 | 1.40 | |
| Operating Profit | 0.62 | 0.36 | 0.44 | 0.46 | 0.32 | -0.06 | 1.94 | -0.11 | -0.11 | -0.09 | -0.13 | 0.27 | -0.05 |
| OPM % | 5.69% | 1.41% | 2.06% | 1.59% | 2.60% | -2.82% | 91.08% | 19.85% | -3.70% | ||||
| 0.00 | -12.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.07 | 0.07 | |
| Interest | 0.00 | 0.16 | 0.20 | 0.27 | 0.23 | 0.22 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.50 | 0.08 | 0.21 | 0.15 | 0.08 | 0.12 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.12 | -12.49 | 0.03 | 0.04 | 0.01 | -0.40 | 1.80 | -0.11 | -0.11 | -0.09 | 0.14 | 0.34 | 0.02 |
| Tax % | 0.00% | 0.40% | 100.00% | 25.00% | 200.00% | 5.00% | 1.11% | 0.00% | 0.00% | 0.00% | 0.00% | 23.53% | |
| 0.12 | -12.54 | 0.00 | 0.04 | -0.02 | -0.42 | 1.78 | -0.11 | -0.11 | -0.09 | 0.14 | 0.26 | -0.06 | |
| EPS in Rs | 0.00 | -0.46 | 0.00 | 0.00 | -0.00 | -0.02 | 0.06 | -0.00 | -0.00 | -0.11 | 0.17 | 0.31 | -0.07 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -25% |
| 5 Years: | -9% |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 39% |
| 5 Years: | -32% |
| 3 Years: | 63% |
| TTM: | -146% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 43% |
| 5 Years: | 173% |
| 3 Years: | 313% |
| 1 Year: | 2716% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 0.30 | 0.30 | 0.32 | 0.32 | 8.41 |
| Reserves | 2.44 | -10.10 | -10.09 | -10.05 | -10.07 | -10.49 | -10.71 | -0.31 | -0.42 | -0.54 | -0.42 | -0.16 |
| 4.97 | 6.15 | 6.83 | 7.49 | 7.53 | 6.56 | 2.02 | 0.00 | 0.13 | 0.18 | 1.61 | 1.66 | |
| 2.54 | 4.61 | 5.57 | 8.19 | 4.12 | 3.81 | 2.59 | 0.02 | 0.04 | 0.10 | 0.05 | 0.65 | |
| Total Liabilities | 20.55 | 11.26 | 12.91 | 16.23 | 12.18 | 10.48 | 4.50 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
| 6.65 | 0.48 | 0.44 | 0.45 | 0.75 | 0.62 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 1.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 4.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7.74 | 10.78 | 12.47 | 15.78 | 11.43 | 9.86 | 4.07 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 | |
| Total Assets | 20.55 | 11.26 | 12.91 | 16.23 | 12.18 | 10.48 | 4.50 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 0.81 | -0.63 | -0.51 | 0.34 | 0.97 | 4.45 | -0.30 | -0.12 | -0.06 | -1.40 | -5.35 | |
| -1.16 | -0.40 | -0.16 | -0.16 | -0.38 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | |
| 0.69 | -0.42 | 0.77 | 0.66 | 0.04 | -0.97 | -4.55 | 0.30 | 0.13 | 0.06 | 1.42 | 8.14 | |
| Net Cash Flow | 0.04 | -0.01 | -0.02 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 2.85 |
| Free Cash Flow | -0.78 | 0.41 | -0.79 | -0.67 | -0.04 | 0.97 | 4.55 | -0.30 | -0.12 | -0.06 | -1.40 | -5.35 |
| CFO/OP | 81% | 225% | -143% | -109% | 112% | -1,650% | 229% | 273% | 109% | 67% | 1,062% | -1,952% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 192.55 | 122.81 | 174.64 | 177.96 | 297.34 | 1,470.28 | 498.66 | 322.06 | ||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 192.55 | 122.81 | 174.64 | 177.96 | 297.34 | 1,470.28 | 498.66 | 322.06 | ||||
| Working Capital Days | 174.46 | 65.13 | 91.59 | 73.58 | 170.33 | 1,041.88 | 260.47 | 214.71 | ||||
| ROCE % | 0.68% | 2.27% | 3.29% | 4.03% | 2.98% | -2.44% | 42.42% | -11.58% | 19.05% | 5.95% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Export Turnover (Foreign Exchange Earnings) INR Lakhs |
|
|||||||||
| Number of Subsidiaries count |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Submission Of Monitoring Agency Report For Utilization Of Proceeds Of Rights Issue Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) For The Quarter Ended June 30, 2026.
- Monitoring agency report for ₹8.08 crore rights issue shows no deviation for quarter ended June 30, 2026.
- Un-Audited Financial Results For The Quarter Ended June 30, 2026
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026 Under Regulation 30 Of SEBI
(LODR) Regulations, 2015
- Board approved Q1 FY27 unaudited standalone results; net loss ₹33.62 lakh.
-
Board Meeting Intimation for The Meeting Of The Board Of The Company Is Scheduled To Be Held On Friday 7, August 2026 Inter-Alia, To Consider, Approve And Take On Record The Unaudited Financial Results Of The Company For The Quarter Ended On June 30, 2026
- Board meeting on 7 August 2026 to approve Q1 FY27 unaudited results; trading window closed from 1 July 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- We are hereby submitting the Certificate issued by Share Transfer Agent of the Company, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, …
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1]
CTL is in the business of providing Information
Technology / Information Technology Enabled Services.